87 results about "Pancreatic tumor" patented technology

The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.

A method and kit for biopsying of the pancreas is disclosed. The biopsy is laparoscopic with a gastroscope. The method is more economic and safer than standard procedures.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.

The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

The invention discloses an application of a Glypican-1 protein in the diagnosis of pancreatic cancer, a detection method of a Glypican-1 positive exosome concentration, and a use of the detection method. A nano-plasma enhanced scattering (nPES) detection technology can be used to quantify exosomes in serum, an exosome extracting process is omitted, the characteristic antigen of the exosomes is used as a target, and the antigen and a corresponding antibody carrying gold nanoparticles form an antigen-antibody complex in order to obtain exosomes, and the amount of the exosomes is reflected by using the light radiation principle of the gold nanoparticles. The Glypican-1 is a pancreatic cancer-derived exosome biomarker, and the content of Glypican-1 positive exosomes in blood plasma has specific specificity even in early pancreatic cancer, so the exosome content index can be used to diagnose the pancreatic cancer, and the exosome level is closely related to the staging and progression of pancreatic cancer patients. Experiments prove that the method using the nPES detection technology to detect the content of the Glypican-1 exosomes in the serum is concise and accurate, and has better sensitivity and specificity than CA19-9 in the diagnosis of the pancreatic cancer.

The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents.

The present invention relates to the use of IL-4 receptor and IL-13 expression as diagnostic and/or prognostic markers for tumors, such as colon and pancreas tumors.

The invention discloses a method for establishing a pancreatic cancer model in a wild-type adult mouse through lentiviruses. The method comprises lentiviral vector construction, virus packaging, titerdetermination and in-vitro verification, virus injection, and pathological identification. The method comprises selecting an oncogene Kras with the highest variation rate of the human pancreatic cancer and cancer suppressor genes of Tp53, Cdkn2a and Cdkn2b, overexpressing the oncogene KrasG12D in the same lentiviral vectors, simultaneously, knocking down Tp53, Cdkn2a and Cdkn2b through shRNA, carrying out virus injection, and after 40 days, detecting significant pancreatic tumors in the adult mouse which is killed by the pancreatic cancer. The method has a short induction period and high andstable incidence, is easy to operate and fast builds the adult mouse pancreatic cancer model. The pancreatic cancer model simulates the genetic mechanism of human pancreatic cancer to the maximum extent, can be used to study the pathogenesis of human pancreatic cancer and the screening of new therapeutic drugs and therapeutic target points and provides a reference for the treatment on human pancreatic cancer.

The invention provides a NGF siRNA-combined gold nanocluster. The NGF siRNA-combined gold nanocluster comprises a gold nanocluster body and NGF siRNA which are combined through the electrostatic adsorption effect. The invention further provides a preparation method of the NGF siRNA-combined gold nanocluster, a drug composition and a reagent box containing the NGF siRNA-combined gold nanocluster and application of the NGF siRNA-combined gold nanocluster in preparation of drugs used for preventing and/or treating cancer. According to the NGF siRNA-combined gold nanocluster, the siRNA stability can be improved, the body-interior circulation time is prolonged, the target ability of pancreatic tumor is improved, the mum effect of NGF is improved, and the anti-tumor treating effect of pancreatic cancer is improved; and the preparation method is simple, the reaction condition is mild, and a new pathway is developed for treating of the pancreatic cancer.

The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.

The invention discloses a pancreatic tumor image segmentation method and system based on reinforcement learning and attention, and the method comprises the steps: extracting an ROI region through a three-dimensional coarse segmentation model, segmenting an ROI region image and an original image into a 2D image along a z axis, selecting two reference layers from the segmented ROI region image through a reinforcement learning network, and carrying out the segmentation of the two reference layers, selecting a segmentation layer from the segmented original image, jointly inputting the segmented original image and the segmented original image into a two-dimensional fine segmentation model with a cross attention feature fusion module, and enabling segmentation features to perform information interaction in the segmentation layer and a reference layer by using the cross attention feature fusion module between the layers to obtain a segmentation result of the pancreatic tumor; according to the method, related information of non-adjacent 2D images is learned by using a cross attention mechanism, so that the limitation that a 2D neural network cannot accurately position a tumor by using interlayer information is avoided, and the problem of inaccurate tumor segmentation caused by redundancy and interference of 3D data information of a 3D neural network is also avoided.

The invention discloses a pancreatic tumor image segmentation method based on dense connection network transfer learning, and the method comprises the steps: obtaining PET (positron emission computed tomography) and MRI (magnetic resonance imaging), carrying out the preprocessing of the PET and MRI, and dividing the PET and MRI into a training set and a test set; constructing a segmentation network, and training the segmentation network by using a PET training data set to obtain a network parameter W1 after one-time training; setting an initial parameter of a feature extraction module in the segmentation network as a value of a corresponding module in W1 by using a migration strategy, randomly initializing parameters of other modules, and retraining the segmentation network by using an MRI image training set to obtain a secondarily trained network parameter W2; and inputting the MRI test set into a segmentation network taking W2 as a network parameter to obtain a segmentation result. The method improves the performance of MRI image segmentation, solves the problem that a network is difficult to train for a small data set in the prior art, and can be used for assisting a doctor to complete automatic target region sketching before pancreatic tumor treatment.

The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK-lipopeptide, at least two co-lipids, therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).

There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ~one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications.; Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70 % to 100 % of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis.

The invention discloses a chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 and a purpose thereof. The chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 comprises an intracellular second transduction domain DAP12, T2A, a CD8alpha signal peptide, anti-human MSLN monoclonal antibody ss1 light chain and heavy chain variable regions MSLN scFv and an intracellular first transduction domain which are connected with each other in series. The chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 disclosed by the invention is used for modifying T lymphocytes; and the modified T cells (CAR-T cells) can be used for treating MSLN positive malignant solid tumors. In a malignant solid tumor killing test, the killing ability of the CAR-T cells to pancreatic tumor cells is obviously enhanced, and good safety and antineoplastic activity are shown in clinical application.